High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma-Reference-Cited by-同舟云学术

High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma

Published:2008-06 Issue: Volume: Page:???-???
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:

Author:

Sasahira Tomonori,Kirita Tadaaki,Oue Naohide,Bhawal Ujjal Kumar,Yamamoto Kazuhiko,Fujii Kiyomu,Ohmori Hitoshi,Luo Yi,Yasui Wataru,Bosserhoff Anja Katrin,Kuniyasu Hiroki

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2008.00894.x/fullpdf

Reference47 articles.

1. Molecular changes in oral cancer may reflect aetiology and ethnic origin;Paterson;Eur J Cancer B Oral Oncol,1996

2. Genome-wide profiling of oral squamous cell carcinoma;Chen;J Pathol,2004

3. Profiling early head and neck cancer;Hunter;Nat Rev Cancer,2005

4. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection;Woolgar;Oral Oncol,1999

5. Molecular markers of the risk of oral cancer;Lippman;N Engl J Med,2001

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contributing Role of High Mobility Group Box 1 Signaling in Oral Cancer Development and Therapy;Life;2023-07-18

2. The Prognostic Significance of FOXD1 Expression in Head and Neck Squamous Cell Carcinoma;Journal of Personalized Medicine;2023-03-15

3. Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer;International Journal of Molecular Sciences;2021-07-29

4. Role of Glycated High Mobility Group Box-1 in Gastric Cancer;International Journal of Molecular Sciences;2021-05-13

5. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway;Bioengineered;2021-01-01